Vibeke Kruse onbezoldigd gastprofessor Publicaties Vibeke Kruse A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced $BRAF^{V600}$ mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitor…

Vibeke Kruse unpaid guest prof. Publications Vibeke Kruse A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced $BRAF^{V600}$ mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors Sour…